Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

Correlation between SARS‐COV‐2 antibody screening by immunoassay and neutralizing antibody testing

(2021) Alfredo Mendrone‐Junior et al.   TRANSFUSION

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

(2021) Noa Dagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination

(2021) Rishi R. Goel et al.   Science Immunology

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

(2021) Sokratis A. Apostolidis et al.   NATURE MEDICINE

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

(2021) Joana Barros-Martins et al.   NATURE MEDICINE

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

(2021) Moriah Bergwerk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis

(2020) F. Schweitzer et al.   JOURNAL OF NEUROLOGY

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

(2020) Syed Faraz Ahmed et al.   Viruses-Basel

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

(2020) Ugur Sahin et al.   NATURE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies

(2020) Elahe Seyed Hosseini et al.   VIROLOGY

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY